Truepill vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
B2B digital pharmacy infrastructure acquired by LetsGetChecked for $525M in Aug 2024; processed 1M+ prescriptions; $322M total funding;
About
Truepill was founded in 2016 as a B2B digital pharmacy infrastructure company, building the backend pharmacy, fulfillment, and telehealth technology that powers consumer-facing digital health brands rather than operating its own direct-to-consumer service. The company's core insight was that dozens of digital health startups — across mental health, weight loss, sexual health, and chronic care — needed licensed pharmacy operations, prescription management, and medication dispensing capabilities but had no efficient path to build them in-house. Truepill became the white-label infrastructure layer enabling companies like Hims & Hers, Ro, and others to offer prescription medications without operating their own pharmacy networks.\n\nTruepill's platform provides end-to-end pharmacy services including prescription intake, clinical review, dispensing from licensed fulfillment pharmacies, last-mile delivery logistics, and patient communication workflows. The company is licensed across all 50 US states and has processed over 1 million prescriptions through its infrastructure. Truepill also built telehealth scheduling and asynchronous care tools, enabling its clients to manage the full care episode from patient intake through diagnosis and medication delivery in a single integrated workflow. This infrastructure-as-a-service model insulated Truepill from direct-to-consumer marketing risk while capturing transaction fees across its customer base.\n\nLetsGetChecked acquired Truepill for $525 million in August 2024, combining Truepill's pharmacy dispensing infrastructure with LetsGetChecked's at-home diagnostic testing platform to create an integrated diagnostics-to-treatment pathway. Truepill had raised $322 million in venture funding prior to the acquisition. The deal reflects a consolidation trend in digital health where diagnostics, prescribing, and pharmacy fulfillment are being integrated into unified platforms that can serve the full clinical workflow from initial testing through ongoing medication management.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.